GlassScriptPhysician profile
Daniel Charles Mulawa
NPI 1205517505
$851.41
in general payments reported to CMS, 2019-2025
17 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.12 · 2024: $308 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $179.34 | 2023-2025 | |
| Exact Sciences Corporation | $111.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.57 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $99.66 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $68.51 | 2024-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $49.57 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $34.29 | 2025 | Austedo Xr |
| Amgen INC. | $34.04 | 2024-2025 | Repatha, Otezla, Otezla |
| Lundbeck LLC | $29.31 | 2025 | Rexulti |
| Alkermes, INC. | $20.03 | 2025 | Vivitrol |
| Tris Pharma INC | $19.14 | 2025 | Dyanavel Xr |
| Abbott Laboratories | $18.84 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $17.49 | 2025 | |
| Sumitomo Pharma America, INC. | $16.99 | 2025 | Gemtesa |
| Dexcom, INC. | $15.03 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.39 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $14.16 | 2025 | Shingrix, Arexvy, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mulawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.